WINDLAS BIOTECH share price has plunged 15% and is presently trading at Rs 740.2.
Meanwhile, the BSE HEALTHCARE index is at 41,030.5 .
Among the top losers in the BSE HEALTHCARE index today are Cadila Healthcare (down 5.6%) and ALEMBIC PHARMA (down 3.1%).
FORTIS HEALTHCARE (up 3.5%) and Aurobindo Pharma (up 3.3%) are among the top gainers today.
Over the last one year, WINDLAS BIOTECH has moved up from Rs 347.1 to Rs 740.2, registering a gain of Rs 393.1 (up 113.3%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,485.8 to 41,030.5, registering a gain of 44.0% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 110.8%), Jubilant Pharmova (up 110.0%) and SUVEN PHARMACEUTICALS (up 103.2%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 78,946.8 (down 0.9%).
The top losers among the BSE Sensex today are HDFC Bank (down 3.3%) and Tata Motors (down 2.2%). The most traded stocks in the BSE Sensex are Reliance Ind. and Tata Steel.
In the meantime, NSE Nifty is at 24,131.7 (down 0.9%). BPCL and HDFC Bank are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,995.8 to 78,946.8, registering a gain of 12,951.0 points (up 19.6%).
WINDLAS BIOTECH net profit grew 48.5% YoY to Rs 170 million for the quarter ended March 2024, compared to a profit of Rs 114 million a year ago. Net sales rose 21.7% to Rs 1,713 million during the period as against Rs 1,407 million in January-March 2023.
For the year ended March 2023, WINDLAS BIOTECH reported 11.9% increase in net profit to Rs 426 million compared to net profit of Rs 381 million during FY22. Revenue of the company grew 10.1% to Rs 5,131 million during FY23.
The current Price to earnings ratio of WINDLAS BIOTECH, based on rolling 12 month earnings, stands at 26.6.
Equitymaster requests your view! Post a comment on "WINDLAS BIOTECH Plunges 15%; BSE HEALTHCARE Index Down 0.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!